Harwood Private Equity invests in Cyprotex

Cyprotex PLC is a leading pharmaceutical contract research company.  It is an outsourced provider of in-vitro and in-silico analysis of the activity of pharmaceutical compounds, specialising in Absorption, Distribution, Metabolism and Excretion and toxicity (“ADME-Tox”) testing.

Harwood Private Equity invested in a convertible and notionally convertible loan note in addition to its 29.9% holding of the ordinary shares of the AIM-listed company.  Harwood has appointed its sector-specialist operational adviser, Ian Johnson, as chairman. Christopher Mills has also joined the board.

Timothy Sturm of Harwood Private Equity, said: “We are pleased to have found a creative way of investing in an excellent company.  We look forward to backing its management team with our capital and influencing the company’s path to its objective of achieving significant growth”.